Alipogene Tiparvovec for the Treatment of LPLD Patients
Status:
Withdrawn
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to provide further confirmatory evidence of clinical benefit in LPLD
patients treated with alipogene tiparvovec by assessing both the "clinical response" (as
defined by a range of parameters), and "the metabolic response" (postprandial CM metabolism)
in LPLD patients with and without an immunosuppressant regimen.